The Terry Fox Laboratory houses two large biohazard Containment Level II+ (CL2+) Facilities, both of which have been designed and tested to meet the requirements outlined in the Canadian Biosafety Standard.
Contact: Vincent Chui, Lab Manager
Ongoing projects in the Viral Vector Laboratory focus on the development of viral vectors for cancer research. Research will involve extensive culturing and manipulation of primary cells from normal and malignant human samples, with the aim of producing recombinant viruses to facilitate payload delivery into mammalian cells for gene therapy and other research studies. The Modified Barrier Facility is managed by the ARC, serves as a quarantine area for new incoming animal strains, and also supports small-scale animal studies prior to strain rederivation.